Evidence map›Paper›PMID 35566025›Full record

ReviewMolecules (Basel, Switzerland)2022

Antimicrobial Mechanisms and Clinical Application Prospects of Antimicrobial Peptides.

Xin Li, Siyao Zuo, Bin Wang, Kaiyu Zhang, Yang Wang

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 118 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
118citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

118 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Adaptive Response ofAntibiotics (Basel, Switzerland) · 2026
    Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Synergistic Action of Antimicrobial Peptides and Antibiotics.International journal of molecular sciences · 2026
    Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Pep5-Cpp, a Cyclin D2-Derived Antimicrobial.Molecules (Basel, Switzerland) · 2026
    Article
  17. Article
  18. Review
  19. Review
  20. Article

58 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xin LiDepartment of Infectious Diseases, First Hospital of Jilin University, Changchun 130021, China.ORCID 0000-0003-4476-3694
Siyao ZuoDepartment of Dermatology and Venereology, First Hospital of Jilin University, Changchun 130021, China.
Bin WangDepartment of Infectious Diseases, First Hospital of Jilin University, Changchun 130021, China.ORCID 0000-0001-6200-0936
Kaiyu ZhangDepartment of Infectious Diseases, First Hospital of Jilin University, Changchun 130021, China.
Yang WangDepartment of Infectious Diseases, First Hospital of Jilin University, Changchun 130021, China.ORCID 0000-0001-8055-9522

Funding

Jilin Provincial Nature Science Foundation of Jilin Provincial Department of Science and Technology 20210101341JCNational Natural Science Foundation of China 81801972Science and Technology Research Project of Jilin Provincial Department of Education JKH20211179KJ
6 · The paper itself

Abstract

Antimicrobial peptides are a type of small-molecule peptide that widely exist in nature and are components of the innate immunity of almost all living things. They play an important role in resisting foreign invading microorganisms. Antimicrobial peptides have a wide range of antibacterial activities against bacteria, fungi, viruses and other microorganisms. They are active against traditional antibiotic-resistant strains and do not easily induce the development of drug resistance. Therefore, they have become a hot spot of medical research and are expected to become a new substitute for fighting microbial infection and represent a new method for treating drug-resistant bacteria. This review briefly introduces the source and structural characteristics of antimicrobial peptides and describes those that have been used against common clinical microorganisms (bacteria, fungi, viruses, and especially coronaviruses), focusing on their antimicrobial mechanism of action and clinical application prospects.

Indexed as

Anti-Infective AgentsVirusesAnti-Bacterial AgentsAntimicrobial Cationic PeptidesAntimicrobial PeptidesBacteriaFungiAnti-Bacterial AgentsAnti-Infective AgentsAntimicrobial Cationic PeptidesAntimicrobial Peptidesantimicrobial mechanismantimicrobial peptidesclinical applicationstructural characteristics

Identifiers

PMID35566025
PMCPMC9104849

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.